Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow ...

Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA) for treating chronic spontaneous urticaria (CSU) in the ...

It has secured regulatory approvals in over 60 nations for various indications encompassing asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, chronic ...

chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, CSU and chronic obstructive pulmonary disease (COPD) in different age populations. More than ...

and prurigo nodularis. Dupilumab is a fully human monoclonal antibody that works by inhibiting the signaling of the IL-4 and IL-13 pathways, according to the company. The data supporting ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...

It is approved for multiple indications, including atopic dermatitis, asthma, prurigo nodularis and eosinophilic esophagitis, as well as chronic obstructive pulmonary disease. The list price of ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...